Spotlight42m
County Exec McCoy allocates nearly $1M for fire training tower renovations
Albany County Executive Daniel McCoy delivered his annual State of the County address on Tuesday, Feb. 18, focusing on ...
The Pharma Letter50m
Odronextamab BLA resubmission accepted for FDA review
The US Food and Drug Administration (FDA) has accepted for review Regeneron Pharmaceuticals’ resubmission of the Biologics ...
JD Supra1h
First Circuit Clarifies FCA Liability Standard for AKS Violations, Deepening Circuit Split
The First Circuit has issued its long-anticipated opinion in United States v. Regeneron Pharmaceuticals, Inc., clarifying the ...
JD Supra2h
In Key Ruling, 1st Circuit Adopts "But-For" Causation Standard for FCA Claims Arising From Unlawful Kickbacks
On February 18, 2025, the U.S. Court of Appeals for the 1st Circuit issued a highly anticipated ruling interpreting the relationship between the ...
Regeneron Pharmaceuticals, Inc.: Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission ...
Regeneron gets FDA Review acceptance for odronextamab's resubmitted BLA
Regeneron Pharmaceuticals (NASDAQ:REGN) said on Wednesday that the U.S. FDA has accepted its resubmitted Biologics License ...
Natera (NTRA) Q4 Earnings: What To Expect
Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results tomorrow after market close. Here’s what to ...
Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission
Regeneron last year won European Commission approval of odronextamab as Ordspono for relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic ...
REGN Lawsuit Alert! Class Action Against Regeneron Pharmaceuticals, Inc.
A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. (REGN) by Levi & Korsinsky on January 7, 2025. The ...
Regeneron announces FDA accepted for review BLA for odronextamab
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted for review the resubmission of the ...
Investing Snacks14h
Regeneron’s Stock Sees Shake-Up as Investors Adjust Stakes
Ieq Capital LLC has reduced its stake in Regeneron Pharmaceuticals by 28%, selling 1,496 shares in the fourth quarter. Other ...
BioWorld23h
Regeneron gene therapy improves childrens’ hearing
In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...